Jamal Isber, MD
Internal Medicine · la Follette, TNNPI 1912936808
Payments from drug & device makers
Across 218 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$855
- GSK$720
- AstraZeneca$245
- Regeneron Healthcare Solutions, Inc.$206
- Insmed, Inc.$178
- Philips North America LLC$171
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,64296%
- Education$1444%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 51 | $855 |
| GSK | 43 | $720 |
| AstraZeneca | 15 | $245 |
| Regeneron Healthcare Solutions, Inc. | 10 | $206 |
| Insmed, Inc. | 10 | $178 |
| Philips North America LLC | 12 | $171 |
| Baxter Healthcare | 6 | $157 |
| Novo Nordisk | 8 | $139 |
| Sunovion Pharmaceuticals Inc. | 9 | $138 |
| Boehringer Ingelheim | 6 | $101 |
| Sanofi-aventis U.S. LLC | 2 | $94 |
| Radius Health, Inc. | 6 | $91 |
| Sanofi | 6 | $91 |
| Merck | 5 | $65 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
| Mylan Specialty L.p. | 3 | $48 |
| Inogen, Inc. | 2 | $48 |
| Advanced Respiratory, Inc | 2 | $47 |
| Inspire Medical Systems, Inc. | 2 | $42 |
| Abbott | 2 | $37 |
| Lilly USA, LLC | 2 | $33 |
| Valeritas, Inc. | 2 | $33 |
| Resmed Corp | 1 | $31 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $23 |
| Bayer | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Medtronic | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Amgen | 1 | $15 |
| Pfizer | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$3,786 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 403 | $416,829 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 22 | $255,217 |
| OzempicSemaglutide | 122 | $185,328 |
| EliquisApixaban | 125 | $124,828 |
| JardianceEmpagliflozin | 116 | $91,438 |
| ForteoTeriparatide | 21 | $88,909 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $65,849 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $49,085 |
| EntrestoSacubitril/Valsartan | 31 | $41,991 |
| JanumetSitagliptin Phos/Metformin Hcl | 42 | $37,010 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $34,816 |
| XareltoRivaroxaban | 23 | $32,599 |
| JanuviaSitagliptin Phosphate | 30 | $23,257 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 682 | $22,691 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $21,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $720 | $492,380518 claims |
| Grifols USA, LLCProlastin C | $855 | $255,21722 claims |
| Novo NordiskOzempic | $139 | $185,328122 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta, Spiriva Respimat | $101 | $143,396192 claims |
| PfizerEliquis | $14 | $124,828125 claims |
| Lilly USA, LLCForteo, Trulicity | $33 | $108,11732 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $245 | $75,91380 claims |
| MerckJanumet, Januvia, Janumet Xr | $65 | $63,84483 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $94 | $10,75312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in la Follette
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.